Literature DB >> 18923396

A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain.

Vadim Yuferov1, Fei Ji, David A Nielsen, Orna Levran, Ann Ho, Susan Morgello, Ruijin Shi, Jurg Ott, Mary Jeanne Kreek.   

Abstract

Dynorphin peptides and the kappa-opioid receptor are important in the rewarding properties of cocaine, heroin, and alcohol. We tested polymorphisms of the prodynorphin gene (PDYN) for association with cocaine dependence and cocaine/alcohol codependence. We genotyped six single nucleotide polymorphisms (SNPs), located in the promoter region, exon 4 coding, and 3' untranslated region, in 106 Caucasians and 204 African Americans who were cocaine dependent, cocaine/alcohol codependent, or controls. In Caucasians, we found point-wise significant associations of 3'UTR SNPs (rs910080, rs910079, and rs2235749) with cocaine dependence and cocaine/alcohol codependence. These SNPs are in high linkage disequilibrium, comprising a haplotype block. The haplotype CCT was significantly experiment-wise associated with cocaine dependence and with combined cocaine dependence and cocaine/alcohol codependence (false discovery rate, q=0.04 and 0.03, respectively). We investigated allele-specific gene expression of PDYN, using SNP rs910079 as a reporter, in postmortem human brains from eight heterozygous subjects, using SNaPshot assay. There was significantly lower expression for C allele (rs910079), with ratios ranging from 0.48 to 0.78, indicating lower expression of the CCT haplotype of PDYN in both the caudate and nucleus accumbens. Analysis of total PDYN expression in 43 postmortem brains also showed significantly lower levels of preprodynorphin mRNA in subjects having the risk CCT haplotype. This study provides evidence that a 3'UTR PDYN haplotype, implicated in vulnerability to develop cocaine addiction and/or cocaine/alcohol codependence, is related to lower mRNA expression of the PDYN gene in human dorsal and ventral striatum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923396      PMCID: PMC2778041          DOI: 10.1038/npp.2008.187

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  57 in total

1.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

2.  Allelic variation in human gene expression.

Authors:  Hai Yan; Weishi Yuan; Victor E Velculescu; Bert Vogelstein; Kenneth W Kinzler
Journal:  Science       Date:  2002-08-16       Impact factor: 47.728

3.  Cis-acting variation in the expression of a high proportion of genes in human brain.

Authors:  Nicholas J Bray; Paul R Buckland; Michael J Owen; Michael C O'Donovan
Journal:  Hum Genet       Date:  2003-05-01       Impact factor: 4.132

4.  Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

5.  Statistical significance for genomewide studies.

Authors:  John D Storey; Robert Tibshirani
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-25       Impact factor: 11.205

Review 6.  Pharmacotherapy of addictions.

Authors:  Mary Jeanne Kreek; K Steven LaForge; Eduardo Butelman
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

7.  An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression.

Authors:  A Zimprich; J Kraus; M Wöltje; P Mayer; E Rauch; V Höllt
Journal:  J Neurochem       Date:  2000-02       Impact factor: 5.372

8.  Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse.

Authors:  Andrew C H Chen; K Steven LaForge; Ann Ho; Pauline F McHugh; Scott Kellogg; Kathy Bell; Rosemary P Schluger; Suzanne M Leal; Mary Jeanne Kreek
Journal:  Am J Med Genet       Date:  2002-05-08

9.  Association of the kappa-opioid system with alcohol dependence.

Authors:  X Xuei; D Dick; L Flury-Wetherill; H-J Tian; A Agrawal; L Bierut; A Goate; K Bucholz; M Schuckit; J Nurnberger; J Tischfield; S Kuperman; B Porjesz; H Begleiter; T Foroud; H J Edenberg
Journal:  Mol Psychiatry       Date:  2006-08-22       Impact factor: 15.992

Review 10.  Untranslated regions of mRNAs.

Authors:  Flavio Mignone; Carmela Gissi; Sabino Liuni; Graziano Pesole
Journal:  Genome Biol       Date:  2002-02-28       Impact factor: 13.583

View more
  38 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 2.  Addiction as a systems failure: focus on adolescence and smoking.

Authors:  Ruben D Baler; Nora D Volkow
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-01-26       Impact factor: 8.829

Review 3.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.

Authors:  Vadim Yuferov; Orna Levran; Dmitri Proudnikov; David A Nielsen; Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

4.  Alcohol dependence, disinhibited behavior and variation in the prodynorphin gene.

Authors:  Janine D Flory; Carolyn L Pytte; Yasmin Hurd; Robert E Ferrell; Stephen B Manuck
Journal:  Biol Psychol       Date:  2011-07-05       Impact factor: 3.251

5.  Genetic diversity and linkage disequilibrium in the chemokine receptor CCR2-CCR5 region among individuals and populations.

Authors:  Collene Lawhorn; Vadim Yuferov; Matthew Randesi; Ann Ho; Susan Morgello; Mary Jeanne Kreek; Orna Levran
Journal:  Cytokine       Date:  2013-09-05       Impact factor: 3.861

Review 6.  Genetics of opiate addiction.

Authors:  Brian Reed; Eduardo R Butelman; Vadim Yuferov; Matthew Randesi; Mary Jeanne Kreek
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

7.  Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence.

Authors:  Matthew Randesi; Wim van den Brink; Orna Levran; Peter Blanken; Eduardo R Butelman; Vadim Yuferov; Joel Correa da Rosa; Jurg Ott; Jan M van Ree; Mary Jeanne Kreek
Journal:  Drug Alcohol Depend       Date:  2016-09-05       Impact factor: 4.492

8.  Expression of ephrin receptors and ligands in postmortem brains of HIV-infected subjects with and without cognitive impairment.

Authors:  Vadim Yuferov; Ann Ho; Susan Morgello; Yaning Yang; Jurg Ott; Mary Jeanne Kreek
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-12       Impact factor: 4.147

9.  Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression.

Authors:  Sarah Ann R Anderson; Michael Michaelides; Parisa Zarnegar; Yanhua Ren; Pernilla Fagergren; Panayotis K Thanos; Gene-Jack Wang; Michael Bannon; John F Neumaier; Eva Keller; Nora D Volkow; Yasmin L Hurd
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

Review 10.  The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective.

Authors:  Sonia Podvin; Tony Yaksh; Vivian Hook
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.